Table 2.
Echocardiographic results. Change in left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular ejection fraction (LVEF) from baseline to last value.
| Ivabradine | Placebo | p | |
|---|---|---|---|
| LVEDV results | n=18 | n=8 | |
| Baseline LVEDV (ml) | 96.0 (79;124.0) | 121.5 (74.5;147.0) | 0.65 |
| Final LVEDV (ml) | 79.0 (70.0;99.0) | 113.5 (103.5;139.0) | 0.01 |
| Change in LVEDV from baseline to last value (ml) | −8.5 (−52.0;7.9) | 30 (−22.0;24.5) | 0.12 |
| LVESV results | n=17 | n=8 | |
| Baseline LVESV (ml) | 50.0 (38.0;65.6) | 52.9 (45.0;83.4) | 0.82 |
| Final LVESV (ml) | 36.0 (32.0;51.0) | 63.5 (49.5;67.3) | 0.03 |
| Change in LVESV from baseline to last value (ml) | −12.0 (−28.0;0.0) | −2.9 (−18.7;17.3) | 0.18 |
| LV ejection fraction | n=23 | n=11 | |
| Baseline LVEF (%) | 50.0 (39.0;57.0) | 45 (40.0;60.0) | 0.95 |
| Final LVEF (%) | 53.0 (42.0;61.0) | 54.0 (43.0;57.0) | 0.74 |
| Change in LVEF from baseline to last value (ml) | 5.0 (−2.0;6.0) | 0.0 (−4.0;4.0) | 0.55 |
Results are presented as median (Q1;Q3).